Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Does QFR-derived physiology stratify high-risk non-infarct-related arteries and guide treatment in patients with acute myocardial infarction?
Result: QFR-derived physiology, including QFR and QFR-PPG, can stratify high-risk non-IRAs and guide optimal treatment in patients with AMI.

“In AMI, combining QFR with QFR-PPG unmasked high-risk non-IRA lesions. Deferred high-risk lesions had strikingly worse 3-year outcomes, whereas PCI was associated with better prognosis in this subgroup. By Sho Nakao https://t.co/PgqtOWqqUH #circ_j #CardioX https://t.co/BGol4BwiFb”
What is the incidence, timing, and clinical significance of immune-mediated myocardial injury and myocarditis after systemic AAV gene therapy?
Result: Immune-mediated myocarditis/myocardial injury occurred in <10 per 100 patient-years, peaking at weeks 1-3, and all events followed intravenous doses >1×10¹³ vector genomes per kilogram body weight.

“Adenovirus remains an important infectious complication following alloHCT, particularly in the setting of evolving GVHD prophylaxis strategies. This journal club will review a contemporary study evaluating the incidence, timing, and clinical outcomes of adenovirus infection in https://t.co/cFyK3KXNgd”
Does the DynamX coronary bioadaptor improve clinical outcomes and restore vessel function compared to conventional drug-eluting stents in patients with coronary artery disease?
Result: The DynamX coronary bioadaptor demonstrated noninferiority to drug-eluting stents with superior late lumen preservation, reduced neointimal hyperplasia, and low target-lesion failure rates, while restoring vessel pulsatility and compliance after 6 months.

“From Caging to Uncaging With Bioadaptors: A Novel Paradigm in Coronary Revascularization | Journal of the American Heart Association https://t.co/umPCKN5822”
Do in-hospital and long-term clinical outcomes differ between acute myocardial infarction patients categorized as SCAI shock stage B versus stage A?

“As compared to SCAI shock modified stage A, modified stage B was not independently associated with in-hospital and long-term clinical outcomes in patients with acute myocardial infarction. By Hisashi Sato and Kenichi Sakakura https://t.co/hM33b1dxhl #circ_rep #CardioX https://t.co/eRcVmgFz7C”
Key Takeaway: Holter-documented non-sustained ventricular tachycardia was modestly associated with an increased risk of appropriate ICD therapy (HR 1.82) but not with ventricular fibrillation or mortality.

“A history of NSVT showed limited prognostic value for primary prevention ICD therapy. Holter-documented NSVT modestly predicted appropriate ICD therapy but was not associated with VF or mortality. By Ryobun Yasuoka https://t.co/DB7T6avwKb #circ_j #CardioX https://t.co/JJIixfQYXM”
Does pedicled internal mammary artery harvesting improve vasorelaxation and clinical outcomes compared to skeletonized harvesting in patients undergoing CABG?
Result: Preservation of perivascular adipose tissue definitively preserves vasorelaxation properties of the IMA, and clinical studies suggest skeletonized harvesting is associated with a higher rate of graft occlusion and worse clinical outcomes than the pedicled technique.
Result: Key gaps in GDMT scores include heterogeneous weighting of drug classes and doses, minimal incorporation of intolerance to identify maximum-tolerated therapy, and heterogeneous incorporation of therapies beyond quadruple therapy.
Result: The RVU model may inadequately capture the full scope of AHF care, potentially contributing to physician burnout and a decline in interest in AHF subspecialty training.

“Compensating Heart Failure Cardiologists: Is the RVU Model the Right Model? | Circulation - https://t.co/ecqCZwZFUf #GoogleAlerts”
Result: Mycn reactivates the cardiomyocyte cell cycle and promotes cardioprotection following ischemic injury, likely via induction of a neonatal-like transcriptional program.
Key Finding: Rapid aortic stenosis progression occurred in 7.8% of patients with sclerosis, 16.4% with mild AS, and 29.8% with moderate AS, with predictors shifting from clinical to valve-related factors.